The Peptide Desk The Peptide Desk

This information is for research and educational purposes only. No medical recommendations. Products are not approved for human use. For health questions, consult a doctor.

Lexicon
Regeneration

BPC + TB Oral Blend

The well-known healing stack as a tablet, mainly meant for the gastrointestinal tract rather than injecting.

1 min read 13 sources

To the product To the sources
White tablet bottle with a black TPD label for BPC + TB Oral Blend on a white podium, next to it two molecule models of blue and white glass spheres in a bright lab
BPC-157 only in phase 1 · not approved

Summary

At a glance

Sources checked on 26 Oct 2026

On the ready-made blend
0 studies

neither on ClinicalTrials.gov nor in PubMed, also none with BPC-157 and TB-500 by mouth12

Only study with both together
32 rats

Achilles tendon, injected into the abdominal cavity, the combination added no benefit2

BPC-157 studies preclinical
35 of 36

systematic review in orthopaedic sports medicine, only one human study9

Wound closure after 7 days
+61 %

thymosin beta-4 in rats with skin wounds, against saline3

  • The tablet combines BPC-157, a peptide from gastric juice, with TB-500, a fragment of thymosin beta-4. There is not a single study on the ready-made blend.125
  • The only study of both peptides together tested Achilles tendon healing in rats. Each on its own was linked to better tissue, TB-500 more clearly, the combination added no benefit.2
  • According to a review BPC-157 is stable in human gastric juice and worked via the drinking water in rats. There are no data on TB-500 taken by mouth.67
  • Almost all data on both components come from animal and cell studies. All published human studies on BPC-157 cover 30 people, none of them oral.910
  • Thymosin beta-4, from which TB-500 is derived, was tested by injection up to phase 2, BPC-157 only up to phase 1. Neither is approved. Everything here is the state of research, not a recommendation.1113
Profile

Updated May 2026

Class
Oral healing blend

BPC + TB

Use
Oral

tablet

Contents
BPC-157 + TB-500

1mg each

WADA
Banned

peptides

Sizes
1 mg

1 size in the shop

Contents 13 sections
  1. At a glance
  2. What is the BPC + TB Oral Blend?
  3. How it works
  4. How to take it
  5. Dosing
  6. What the research shows
  7. Research status
  8. Side effects
  9. Storage
  10. Related compounds
  11. FAQ
  12. Glossary
  13. Sources

What is the BPC + TB Oral Blend?

This blend brings the two healing peptides BPC-157 and TB-500 in tablet form, 1mg each. Unlike the injectable variant, the oral form is mainly meant for the gastrointestinal tract, where BPC-157 originally comes from.

Comparison

BPC-157 and TB-500 in different forms

The tablet next to the single compounds and the blend for injection, as stated in the TPD lexicon. Tap a card to open its entry.

Tablet with both BPC + TB Oral Blend BPC-157 TB-500 2 of 2 compounds
Blend for injection BPC + TB Blend BPC-157 TB-500 2 of 2 compounds BPC-157 as a tablet BPC-157 Oral (Tablet) BPC-157 TB-500 1 of 2 compounds TB-500 for injection TB-500 (Thymosin Beta-4) BPC-157 TB-500 1 of 2 compounds

Simplified: the same components do not mean the same effect. In humans only the single compounds by injection or infusion have been studied so far. 210

How it works

BPC-157 originally comes from gastric juice and is closely tied to gastrointestinal healing, which makes oral use sensible. TB-500 acts on cell migration and new vessel formation. With oral intake, however, systemic absorption is limited, the effect is likely strongest locally in the digestive tract.

The individual mechanisms are in the lexicon entries for BPC-157 and TB-500.

Where it acts

Components and where they act

Tap a point or a card. Colour = component, all sites from animal studies on the single compound.

  1. Stomach and oesophagus

    BPC-157 protected the mucosa against alcohol and painkiller damage (rats)6

    BPC-157
  2. Gut

    Colon-skin fistulas also healed with BPC-157 in the drinking water (rats)7

    BPC-157
  3. Skin and wounds

    Thymosin beta-4 sped up wound closure by up to 61 percent (rats)3

    TB-500
  4. Achilles tendon

    Better tendon tissue on their own, above all with TB-500, no added benefit together (rats)2

    BPC-157TB-500
  5. Liver and kidney

    BPC-157 is broken down quickly, excreted via urine and bile (rats, dogs)8

    Observed in trials
Stomach and intestine of translucent glass with soft folds, small blue molecules spread along the inner wall
Taken orally, most plausibly local in the digestive tract. Symbolic image.

How to take it

Oral, usually one tablet per day with some water, with or without food.

Closed white tablet bottle with a black TPD label for BPC + TB Oral Blend, a glass of water and a few white tablets beside it on a white tray
One tablet with some water, as described in the entry. Symbolic image.

Dosing

Dosing

Dosing, titration and syringe

Loading the dosing information …

  • Getting started and stepping up, drawn as a staircase
  • Units on the U-100 syringe for every step
  • How long one vial lasts

What the research shows

BPC-157 is preclinically closely tied to gastrointestinal healing, TB-500/thymosin beta-4 to tissue regeneration (Crockford, 2010). On oral bioavailability in humans the data is thin. Honestly: plausible for local gut effects, for systemic action the injection is the better-evidenced route.

Study results

What the trials measured

Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.

Where the knowledge on BPC-157 comes from9

Share of the 36 studies in a systematic review (literature up to June 2024)

Systematic review9 35 preclinical, 1 clinical study
Animal and cell studies 97.2%
Human studies 2.8%

The only human study in the review was a retrospective analysis of knee injections. According to a review there are hardly any human safety data on TB-500.

Wound healing with thymosin beta-4 in rats3

More than in the saline control group, applied to the skin or into the abdominal cavity

New skin after 4 days3
Thymosin beta-4 (rat) 42%
New skin after 7 days3
Thymosin beta-4 (rat) 61%
Wound contraction after 7 days3
Thymosin beta-4 (rat) 11%

Study with full thymosin beta-4, not with the TB-500 fragment and not by mouth.

Participants by route10

Share of the 30 people from all three published human studies on BPC-157 (review up to June 2026)

Systematic review10 16 into the knee, 12 into the bladder, 2 into a vein, 0 by mouth
Into the knee 53.3%
Into the bladder 40.0%
Into a vein 6.7%
By mouth 0.0%

All three studies without a control group, the review rates the certainty of evidence as very low.

Top view of petri dishes, a pipette and a glass of water around a frosted glass stomach model
There is no study on the blend, only on the components. Symbolic image.

Research status

Where the research stands

There is no study on the blend. Shown are registered trials on the single components, almost all injected or infused. Thymosin beta-4 reached phase 3 as eye drops, which is not listed here. As of 26 Oct 2026. 11

  1. Preclinical Both together only in one rat study, without added benefit
  2. Phase 1 3 trials on components, 2 completed
  3. Phase 2 3 trials on components, 2 completed
  4. Phase 3 no registered trial
  5. Approval not yet
Not approved. ChEMBL lists BPC-157 with phase 1 and thymosin beta-4 with phase 3 (eye drops) as the highest phase, neither approved.13
Show all 4 trials on a timelineHide timeline 3 completed 1 running 0 with results
Phase 2
Without phase

Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026. Phase 1: 3 trials on safety and pharmacokinetics, not shown as bars.

Side effects

  • Generally well tolerated.
  • Solid human data on the oral form are largely missing.

Tolerability

Side effects in the human studies on BPC-157

Out of 100 participants, how many had a treatment-related side effect. Three small BPC-157 studies without placebo, none with the blend.

0 of 100 Participants
Event Participants
Treatment-related side effects10 0%

Zero does not mean safe here. 40 healthy people tolerated thymosin beta-4 into a vein without serious side effects. There are no data on the tablet with both peptides.104

Storage

Store dry, cool and protected from light, out of reach of children. Keep the original container closed and mind the expiry date.

Three white tablet bottles on a bright shelf next to a folded light blue towel
Dry, cool and away from light, bottle closed. Symbolic image.

Related

Related compounds

Same compounds, blends with BPC + TB Oral Blend or a different path: all in the TPD lexicon.

BPC + TB Oral Blend
BPC + TB Blend The same components for injection BPC-157 Oral (Tablet) Only BPC-157 as a tablet BPC-157 Oral (Capsule) Only BPC-157 as a capsule BPC-157 Main entry, BPC-157 as an injection TB-500 (Thymosin Beta-4) Main entry, TB-500 as an injection Klow Blend Contains both plus GHK-Cu and KPV KPV Oral Different peptide as a tablet focused on the gut

FAQ

Common questions about BPC + TB Oral Blend

Short answers, each backed by the sources below.

Are there studies on this tablet?

No. As of 26 October 2026 there is no study of BPC-157 and TB-500 together taken by mouth, neither on ClinicalTrials.gov nor in PubMed. Everything here comes from studies on the single compounds.12

Do both work better together?

That is not established. In the only study of both peptides together (Achilles tendon in 32 rats, injected into the abdominal cavity) each on its own was linked to better tendon tissue, significantly above all with TB-500, which also raised tensile strength. The combination gave no advantage over either alone. The authors suspect shared signalling pathways.2

What is TB-500?

TB-500 is sold as a fragment of thymosin beta-4. Thymosin beta-4 binds the structural protein actin in cells and is linked to cell migration, new vessel formation and tissue repair. A 2026 review finds hardly any solid human safety data for TB-500.15

Are the peptides absorbed by mouth?

For BPC-157 there are hints from animal studies: according to a review it is stable in human gastric juice and worked via the drinking water in rats. There are no blood measurements after oral dosing. For TB-500 by mouth there are no data at all.67

Which trials are running on the components?

As of 26 October 2026 no trial in which a component is injected is recruiting. Announced are a phase 1 trial of BPC-157 under the skin after shoulder surgery and a third phase 2 trial of thymosin beta-4 after heart attack. Two phase 2 trials of thymosin beta-4 after heart attack are completed. A study of gummies with BPC-157 is completed, results are still missing.11

Which side effects are known?

None for the tablet. No treatment-related side effects occurred in the three small human studies on BPC-157, but the certainty is very low. 40 healthy people tolerated thymosin beta-4 into a vein without serious side effects. One review warns of risks from unregulated manufacturing.1049

Glossary

Terms explained briefly

Dotted words in the text open these explanations directly.

Actin
Structural protein of the cell skeleton, needed for cell shape and movement.
Bioavailability
The share of a substance that actually reaches the blood after dosing.
Cell migration
Movement of cells to a wound or into new tissue, a basic step of healing.
Fistula
An abnormal connection between two organs or between an organ and the skin, for example between gut and skin.
Gastric juice
Acidic fluid in the stomach that breaks down many proteins and peptides. BPC-157 was derived from a protein in it.
New vessel formation
The formation of new small blood vessels, for example in healing tissue.
Preclinical
Research before first use in humans, in cell cultures and animal models.
Systematic review
An analysis of all studies on one question following fixed rules. Shows how much research there is and how good it is.
Systemic
Acting throughout the body, spread via the blood. The opposite is local, only at the site of dosing.
Thymosin beta-4
The body's own peptide that binds actin in cells. TB-500 is regarded as a fragment of it.
WADA
World Anti-Doping Agency. Its prohibited list applies to competitive sport.

Evidence

Sources

Show all 13 sourcesHide sources 9 Studies2 Trial registry2 Database checked 26 Oct 2026

Studies

  1. BPC-157, TB-500 and both together in Achilles tendon healing (rats)

    Biçer et al., Joint Diseases and Related Surgery, 2026

    DOI 10.52312/jdrs.2026.2951 PMID 42542926
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  2. Thymosin beta-4 accelerates wound healing (rats)

    Malinda et al., Journal of Investigative Dermatology, 1999

    DOI 10.1046/j.1523-1747.1999.00708.x PMID 10469335
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  3. Thymosin beta-4 into a vein in 40 healthy adults

    Ruff et al., Annals of the New York Academy of Sciences, 2010

    DOI 10.1111/j.1749-6632.2010.05474.x PMID 20536472
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  4. Review of approved and unapproved peptides in sport

    Mendias et al., Sports Medicine, 2026

    DOI 10.1007/s40279-026-02437-0 PMID 41966639
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  5. Review of BPC-157 in the gastrointestinal tract

    Sikiric et al., Current Pharmaceutical Design, 2011

    DOI 10.2174/138161211796196954 PMID 21548867
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  6. BPC-157 injected or in drinking water for colocutaneous fistulas (rats)

    Klicek et al., Journal of Pharmacological Sciences, 2008

    DOI 10.1254/jphs.fp0072161 PMID 18818478
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  7. Absorption, distribution and breakdown of BPC-157 (rats, dogs)

    He et al., Frontiers in Pharmacology, 2022

    DOI 10.3389/fphar.2022.1026182 PMID 36588717
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  8. Systematic review of BPC-157 in orthopaedic sports medicine

    Vasireddi et al., HSS Journal, 2025

    DOI 10.1177/15563316251355551 PMID 40756949
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  9. Systematic review of all human studies on BPC-157

    Poolton et al., Acta Orthopaedica Belgica, 2026

    DOI 10.52628/92.3.15837 PMID 42885452
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed

Trial registry

  1. Trials on the components on ClinicalTrials.gov

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2
  2. Registry search for both together (0 results)

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2

Database

  1. Review of the structure and function of thymosin beta-4 (PubMed record)

    Crockford et al., Annals of the New York Academy of Sciences, 2010

    PMID 20536467
    Checked 26 Oct 2026 via PubMed, doi.org, Crossref
  2. BPC-157 and thymosin beta-4 in ChEMBL

    ChEMBL, EMBL-EBI (CHEMBL4297358, CHEMBL4594314)

    Checked 26 Oct 2026 via ChEMBL

In the shop

BPC + TB Oral Blend in the catalog

Sizes, prices and shipping times are on the product page.

To the product